We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-19.85%
Top 10 Holdings %
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$203M |
| 2 |
Gilead Sciences
GILD
|
+$156M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$146M |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$350M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$235M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$225M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Miscellaneous | 0.05% |
| 5 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Oracle
ORCL
$408B
| $28.1K | ﹤0.01% |
191
-12
| -6% | -$1.95K |
2023 Q4
9 quarters
|
|
152
Quest Diagnostics
DGX
$26.4B
| $25.7K | ﹤0.01% |
131
-7,149
| -98% | -$1.39M |
2025 Q2
3 quarters
|
|
153
Qualcomm
QCOM
$191B
| $25.4K | ﹤0.01% |
197
-12
| -6% | -$1.75K |
2023 Q4
9 quarters
|
|
154
Recursion Pharmaceuticals
RXRX
$2.23B
| $14.2K | ﹤0.01% |
4,627
-294
| -6% | -$1.14K |
2023 Q3
10 quarters
|
|
155
Qiagen
QGEN
$9.53B
| $9.73K | ﹤0.01% |
+243
| New | +$11.5K |
2026 Q1
0 quarters
|
|
156
Amneal Pharmaceuticals
AMRX
$6.7B
| – | – |
-7,913
| Closed | -$99.7K | – |
|
157
Arista Networks
ANET
$234B
| – | – |
-4,800
| Closed | -$629K | – |
|
158
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-4,210
| Closed | -$106K | – |
|
159
Avantor
AVTR
$10.9B
| – | – |
-276,266
| Closed | -$3.17M | – |
|
160
AstraZeneca
AZN
$259B
| – | – |
-15,216
| Closed | -$2.8M | – |
|
161
Beam Therapeutics
BEAM
$2.55B
| – | – |
-111,510
| Closed | -$3.09M | – |
|
162
Brookdale Senior Living
BKD
$2.41B
| – | – |
-167,444
| Closed | -$1.81M | – |
|
163
BioMarin Pharmaceuticals
BMRN
$10.8B
| – | – |
-65,008
| Closed | -$3.86M | – |
|
164
CareDx
CDNA
$3.45B
| – | – |
-431,070
| Closed | -$8.12M | – |
|
165
CG Oncology
CGON
$5.48B
| – | – |
-3,095
| Closed | -$129K | – |
|
166
Compass Pathways
CMPS
$1.61B
| – | – |
-142,243
| Closed | -$981K | – |
|
167
Corcept Therapeutics
CORT
$12.3B
| – | – |
-10,495
| Closed | -$365K | – |
|
168
Doximity
DOCS
$5.61B
| – | – |
-11,817
| Closed | -$523K | – |
|
169
DELISTED
Exact Sciences
EXAS
| – | – |
-16,062
| Closed | -$1.63M | – |
|
170
Exelixis
EXEL
$15.6B
| – | – |
-7,361
| Closed | -$323K | – |
|
|
171
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-10,735,195
| Closed | -$153M | – |
|
172
Guardant Health
GH
$22.3B
| – | – |
-3,004
| Closed | -$307K | – |
|
173
Genmab
GMAB
$23.3B
| – | – |
-3,009
| Closed | -$92.7K | – |
|
174
Icon
ICLR
$13.5B
| – | – |
-24,560
| Closed | -$4.48M | – |
|
175
IDEAYA Biosciences
IDYA
$3.27B
| – | – |
-4,942
| Closed | -$171K | – |
|
Similar funds
PTC
Bellevue Group's Q1 2026 Portfolio in Review
As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.
Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.
- Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
- Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
- Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
- Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
- Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
- Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.